Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).

What symbol and exchange does Apnimed shares trade?

Apnimed trades on the NASDAQ stock market under the symbol APMD.

What is Apnimed stock price doing today?

As of November 10, 2026, APMD stock price climbed to $15.86 with 371,559 million shares trading.

What is Apnimed's Beta?

APMD has a beta of 0.95, meaning it tends to be less sensitive to market movements. APMD has a correlation of 0.01 to the broad based SPY ETF.

How much is Apnimed worth?

APMD has a market cap of $660.14 million. This is considered a Small Cap stock.

What are the top ETFs holding Apnimed?

The top ETF exchange traded funds that APMD belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWO.

What are the support and resistance levels for Apnimed (APMD)?

APMD support price is $14.82 and resistance is $16.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APMD shares will trade within this expected range on the day.